Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Feb 23, 2021 7:58am
154 Views
Post# 32634580

RE:Q1 Financials

RE:Q1 Financials

Q4 & full year results came out end of March last year ( for 2019) 
I'm expecting similar timing for 2020 results. 

"If a deal has already been shook upon" I'm thinking that was only for half the marbles, and because it is probably results dependent ( interim?) the buyer has the ability to walk away. Meaning a US listing still has merit and possibilities. It's unclear whether the seller wants to rely on market forces for value discovery. As you say, based on past efforts, it's hard to imagine them changing ... but remains a possibility. 

I think potential buyers can/should appreciate the value, but the general public ( and hence market) still struggles to understand the magnitude of Sepsis story. 


MM
 

<< Previous
Bullboard Posts
Next >>